BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28159621)

  • 1. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases.
    Giacomelli C; Daniele S; Martini C
    Biochem Pharmacol; 2017 May; 131():1-15. PubMed ID: 28159621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathology of synuclein aggregates.
    Duda JE; Lee VM; Trojanowski JQ
    J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.
    Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B
    Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.
    Takeda A; Mallory M; Sundsmo M; Honer W; Hansen L; Masliah E
    Am J Pathol; 1998 Feb; 152(2):367-72. PubMed ID: 9466562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
    El-Agnaf OM; Irvine GB
    J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
    Lee VM; Giasson BI; Trojanowski JQ
    Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
    Liu J; Mouradian MM
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
    Windisch M; Hutter-Paier B; Schreiner E; Wronski R
    J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.
    Valiente-Gabioud AA; Miotto MC; Chesta ME; Lombardo V; Binolfi A; Fernández CO
    Acc Chem Res; 2016 May; 49(5):801-8. PubMed ID: 27136297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein aggregation and ER stress.
    Ogen-Shtern N; Ben David T; Lederkremer GZ
    Brain Res; 2016 Oct; 1648(Pt B):658-666. PubMed ID: 27037184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein: its biological function and role in neurodegenerative diseases.
    Kaplan B; Ratner V; Haas E
    J Mol Neurosci; 2003 Apr; 20(2):83-92. PubMed ID: 12794302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila.
    Poças GM; Branco-Santos J; Herrera F; Outeiro TF; Domingos PM
    Hum Mol Genet; 2015 Apr; 24(7):1898-907. PubMed ID: 25452431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.
    Sierks MR; Chatterjee G; McGraw C; Kasturirangan S; Schulz P; Prasad S
    Integr Biol (Camb); 2011 Dec; 3(12):1188-96. PubMed ID: 22076255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation and synergistic fibrillization of tau and alpha-synuclein.
    Giasson BI; Forman MS; Higuchi M; Golbe LI; Graves CL; Kotzbauer PT; Trojanowski JQ; Lee VM
    Science; 2003 Apr; 300(5619):636-40. PubMed ID: 12714745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
    Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
    Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives.
    Lee SJ; Lim HS; Masliah E; Lee HJ
    Neurosci Res; 2011 Aug; 70(4):339-48. PubMed ID: 21624403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.